Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome

NCT00551343 · Completed

Last updated 2026-05-28

This clinical trial is studying gut-derived hormones, body composition, and metabolism in people with Prader-Willi Syndrome.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 20 people

Who can join Ages 18–45 · all sexes Healthy volunteers accepted.

Timeline Started 2007-10 · est. completion 2008-09

Where 1 site · Australia

What this study is testing ClinicalTrials.gov NCT00551343 ↗

Description as written by the study sponsor.

The purpose of this study is to investigate the effects of a GLP-1 agonist on satiety hormones in patients with Prader-Willi Syndrome (genetic defect causing obesity).

Treatments tested

Exenatide Drug

10ug Exenatide single s.c. injection

Main thing measured	satiety hormones
Sponsor	Garvan Institute of Medical Research
Conditions studied	Prader-Willi Syndrome
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00551343 ↗